Research Paper Volume 15, Issue 10 pp 4444—4464
Development and validation of a novel T cell proliferation-related prognostic model for predicting survival and immunotherapy benefits in melanoma
Figure 9. (A–L) Therapeutic drugs showed significant differences in IC50 between the high- and low-risk groups.